Clinical Trial Update: Orelabrutinib in the Treatment of Relapsed/Refractory AIHA [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Orelabrutinib for relapsed/refractory autoimmune hemolytic anemia. The study status is Not yet Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Autoimmune Hemolytic Anemia (AIHA) | Phase 2 | Status: NOT_YET_RECRUITING